Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
Beckley Psytech
Every issue covering Beckley Psytech.
3 issues
2026-08-25
No. 11
Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.
TRIALS
REGULATORY
LILLY
ATAIBECKLEY
BECKLEY-PSYTECH
REGION-SKANE
2026-07-07
No. 5
European psychedelic depression development just split into two camps.
TRIALS
COMPASS
BECKLEY-PSYTECH
CYBIN
2026-06-11
European Psychedelic Medicine: H1 2026 in Review
RESEARCH
DEALS
COMPASS
ATAIBECKLEY
BECKLEY-PSYTECH
GH